Merck & Co restores faith in first-line future for Keytruda lung cancer combo

17 January 2018

Shares in New Jersey, USA-based Merck & Co (NYSE: MRK) gained 6% yesterday after the company announced its Phase III KEYNOTE-189 trial of Keytruda (pembrolizumab) met its co-primary endpoints, boosting confidence in its ability to lead in the market for first-line lung cancer therapies.

The trial is designed to compare a combination of the checkpoint inhibitor with Alimta (pemetrexed) and cisplatin or carboplatin, with Alimta and chemo alone, for the first-line treatment of patients with non-small cell lung cancer (NSCLC).

Roger Perlmutter, president of Merck’s research division said the study “showed significant improvement in overall survival and progression-free survival for patients receiving Keytruda.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK